Marc Oczachowski is Chairman of the Board and Chief Executive Officer of EDAP TMS, a high-tech medical company which develops, manufactures markets minimally invasive therapeutic ultrasound solutions for urology, tumor removal, localized prostate cancer, and infectious diseases.
Read more
janv. 14, 2021
Positive 24 month interim results of French Urology Association (AFU) sponsored clinical trial study comparing HIFU to radical prostate surgery: results on 3,329 patients demonstrate significant difference in efficacy in favor of HIFU versus Radical Prostatectomy (RP).
Read more
déc. 17, 2020
EDAP TMS and #HIFU users are handling the situation with COVID-19 when elective procedures are currently being put on-hold.
Read more
déc. 9, 2020
U.S. Centers for Medicare and Medicaid Services (CMS) has issued its final rules establishing, for the first time, a Category 1 CPT code which facilitates reimbursement for the ablation of malignant prostate tissue with HIFU technology, effective January 1, 2021.
Read more
sept. 3, 2020
the first two patients have been treated in the company’s Phase 2 clinical trial assessing Focal One® High Intensity Focused Ultrasound (HIFU) as a potential treatment for deep rectal endometriosis. A total of 38 women will be enrolled in the study and treated at five major hospitals and assessed over a six-month follow-up period.
Read more
.png)
